Tenaya Therapeutics, Inc.
$0.74
▲
2%
2026-04-21 09:51:01
www.tenayatherapeutics.com
NMS: TNYA
Explore Tenaya Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$169.71 M
Current Price
$0.74
52W High / Low
$2.35 / $0.36
Stock P/E
—
Book Value
$0.57
Dividend Yield
—
ROCE
-70.98%
ROE
-83.84%
Face Value
—
EPS
$-0.59
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
70
Beta
3
Debt / Equity
8.79
Current Ratio
6.84
Quick Ratio
6.84
Forward P/E
-1.53
Price / Sales
—
Enterprise Value
$60.01 M
EV / EBITDA
-0.71
EV / Revenue
—
Rating
None
Target Price
$9
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Alpha Tau Medical Ltd. | $8.11 | — | $706.72 M | — | -44.45% | -61% | $8.6 / $2.5 | $0.88 |
| 2. | NeurAxis, Inc. | $7 | — | $80.77 M | — | -216.78% | -2.85% | $7.97 / $1.33 | $0.32 |
| 3. | Celularity Inc. | $1.24 | — | $35.47 M | — | -48.8% | -232.51% | $4.35 / $1.01 | $-0.71 |
| 4. | Cadrenal Therapeutics, Inc. | $5.25 | — | $13.09 M | — | -491.51% | -2.6% | $17.5 / $4.21 | $1.17 |
| 5. | Boundless Bio, Inc. | $1.6 | — | $35.4 M | — | -43.97% | -46.69% | $1.78 / $0.96 | $4.4 |
| 6. | Royalty Pharma plc | $49.52 | 27.78 | $28.52 B | 1.91% | 8.21% | 13.2% | $50.08 / $31.58 | $15.11 |
| 7. | Viridian Therapeutics, Inc. | $14.68 | — | $1.5 B | — | -43.85% | -49.16% | $34.29 / $11.76 | $5.79 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -20.77 M | -20.94 M | -24.08 M | -27.54 M | -24.65 M |
| Net Profit | -20.18 M | -20.27 M | -23.28 M | -26.86 M | -23.84 M |
| EPS in Rs | -0.09 | -0.09 | -0.11 | -0.12 | -0.11 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -93.33 M | -115.95 M | -131.19 M | -125.62 M |
| Net Profit | -90.6 M | -111.13 M | -124.08 M | -123.67 M |
| EPS in Rs | -0.42 | -0.51 | -0.57 | -0.57 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 146.92 M | 119.94 M | 170.51 M | 278.94 M |
| Total Liabilities | 23.66 M | 27.09 M | 31.09 M | 35.57 M |
| Equity | 123.27 M | 92.85 M | 139.42 M | 243.38 M |
| Current Assets | 105.59 M | 67.38 M | 111.58 M | 193.75 M |
| Current Liabilities | 15.44 M | 15.97 M | 22.73 M | 24.25 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -68.26 M | -90.5 M | -102.07 M | -104.42 M |
| Investing CF | 56.08 M | 1.13 M | 48.72 M | 83.65 M |
| Financing CF | 108.41 M | 47.75 M | 4.05 M | 77.77 M |
| Free CF | -68.88 M | -91.53 M | -103.31 M | -125.05 M |
| Capex | -0.62 M | -1.02 M | -1.24 M | -20.63 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 10.44% | -0.34% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.